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The complement activation product, C5a, is a key factor for regulation of inflammatory
responses. C5a and C5adesArg bind to their receptors, C5aR and C5L2, but the functional
roles of C5L2 remain controversial. We screened the patterns of 23 inflammatory medi-
ators in cultures of LPS-activated mouse peritoneal elicited macrophages (PEMs) in the
presence or absence of recombinant mouse C5a. Production of most mediators studied
was suppressed by C5a, whereas G-CSF production was enhanced. G-CSF gene expres-
sion and secretion from PEMs was amplified two- to threefold by C5a in a dose- and
time-dependent fashion. The degradation product C5adesArg promoted lower levels of
G-CSF. The effects of C5a on G-CSF were associated with activation of PI3K/Akt and
MEK1/2 signaling pathways. C5a did not enhance G-CSF production in cultures of PEMs
from either C5aR- or C5L2-deficient mice, indicating that both C5a receptors are indis-
pensable for mediating the effects of C5a in the production of G-CSF. Finally, G-CSF levels
in plasma during polymicrobial sepsis after cecal ligation and puncture were substan-
tially lower in C5aR- or C5L2-deficient mice as compared with that in C57BL/6J WT mice.
These findings elucidate the functional characteristics of the C5L2 receptor during the
acute inflammatory response.
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Introduction
Proteolytic cleavage of complement proteins following activation
of the classical, alternative, and lectin pathways can generate
substantial quantities of the anaphylatoxin, complement activa-
tion fragment (C5a) [1]. Rapid inactivation by carboxypeptidase
removes the C-terminal arginine, converting C5a to C5a lacking
the C-terminal arginine (C5adesArg). Both C5a and C5adesArg (with
much lower affinity) are ligands for the G-protein coupled C5aR
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receptor (CD88) [2, 3]. C5aR is abundantly expressed on innate
immune cells of the myeloid lineage, lymphocytes, and in lower
numbers on epithelial and endothelial cells [4–6]. In polymor-
phonuclear leukocytes (PMNs) and macrophages, ligation of C5a
with the C5aR receptor leads to rapid buildup of cytosolic Ca2+,
activation of MAPK signaling pathways, chemotaxis, respiratory
burst, release of toxic granules, and regulation of cytokine expres-
sion [2,3,7].
A second C5a receptor, C5L2 (GPR77), has been identified [8].
Initially, C5a was thought to be a nonsignaling “decoy” recep-
tor [8]. Indeed, binding of C5a or C5adesArg to C5L2 does not
induce rapid Ca2+ currents [9]. However, accumulating evidence
suggests distinct functional roles of C5L2 in disease. For exam-
ple, both C5aR and C5L2 receptors are critical factors during
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polymicrobial sepsis after cecal ligation and puncture (CLP) [10].
The expression of C5L2 in PMNs is downregulated during severe
sepsis, which is a marker of poor prognosis [11]. C5L2 determines
the outcome of experimental allergic asthma [12]. Polymorphisms
of the C5L2 gene may be associated with a higher risk for cardio-
vascular diseases in some populations [13]. Despite these findings,
many aspects of the role of C5L2 in acute and chronic inflamma-
tion remain enigmatic.
In this report, we describe that C5a promotes the release of
G-CSF. These effects required the presence of both C5aR and C5L2
in cultures of macrophages and during polymicrobial sepsis after
CLP.
Results and discussion
Differential regulation of mediator production by C5a
We have recently reported that the production of several cytokines
(IL-17, IL-23, and IL-27) is suppressed by C5a when present in
cultures of LPS-activated peritoneal elicited macrophages (PEMs)
[5, 14, 15]. To investigate how broad the spectrum of C5a-
regulated mediators is, the concentrations of 23 inflammatory
mediators were analyzed by a multiplexing bead-based assay
(Table 1). Incubation of PEMs from C57BL/6J mice with LPS for
10 h generally increased the release of cytokines and chemokines
as compared to untreated control PEMs (Table 1). Simultaneous
addition of recombinant mouse C5a (100 nM) to LPS-activated
PEMs affected the production of all mediators studied (Table 1).
Although proinflammatory mediators were suppressed by C5a, the
remarkable finding was that only IL-10 and G-CSF were amplified
(by 103 and 197%, respectively). No consistent effects on produc-
tion of the analyzed cytokines was observed, when C5a was used
alone in PEMs (data not shown; [5, 15]). It has been reported
previously that cytokines of the IL-12 family are antagonized by
C5a [16,17]. Furthermore, we have recently described the role of
C5a-induced IL-10 in downmodulation of the IL-17A/IL-23 axis
[15]. These findings demonstrate that the strong proinflamma-
tory anaphylatoxin C5a in high concentrations can mediate anti-
inflammatory effects in primed macrophages, which may be bene-
ficial to prevent excessive inflammation. Reciprocal effects of C5a
(as an inducer of proinflammatory cytokines/chemokines) have
been noted in other cell types such as alveolar epithelial cells
[18], microvascular endothelial cells [19], or blood PMNs [20].
C5a promotes release of G-CSF via Akt and MEK1/2
The current studies were focused on G-CSF, which was the medi-
ator most potently enhanced by C5a in PEMs (Table 1). C5a acted
dose dependently to increase G-CSF levels by two to threefold in
cultures of PEMs (Fig. 1A). Higher concentrations of G-CSF were
observed at all time points (3–24 h) studied (Fig. 1B). Long-lasting
modulation of mediator release by C5a has been also reported
for other cytokines [5,15]. Recombinant C5adesArg in combination
Table 1. Regulation of macrophage-derived mediators by C5.a)
Mediator CTRL LPS LPS + C5a
(pg/mL) (pg/mL) (% change)
IL-1α 36 ± 19 388 ± 94 −30**
IL-1β 255 ± 166 2800 ± 683 −30*
IL-2 44 ± 13 83 ± 18 −23*
IL-3 5 ± 2 19 ± 5 −29*
IL-4 9 ± 3 29 ± 8 −22*
IL-5 6 ± 3 15 ± 3 −27*
IL-6 89 ± 46 5516 ± 1455 −64**
IL-9 57 ± 17 350 ± 74 −38**
IL-10 62 ± 21 223 ± 41 +103*
IL-12(p40) 157 ± 66 12 983 ± 4366 −81**
IL-12(p70) 73 ± 20 1427 ± 344 −68*
IL-13 109 ± 60 979 ± 268 −35*
IL-17 43 ± 26 1036 ± 375 −44*
Eotaxin 461 ± 185 2653 ± 613 −30***
G-CSF 38 ± 22 375 ± 59 +197**
GM-CSF 43 ± 12 161 ± 31 −21*
IFN-γ 31 ± 9 279 ± 39 −47*
KC 1148 ± 791 26 097 ± 2087 −28*
MCP-1 1124 ± 663 19 722 ± 4038 −55**
MIP-1α 457 ± 256 21 528 ± 6056 −69**
MIP-1β 2323 ± 1485 130 564 ± 37 936 −60**
RANTES 550 ± 276 22 212 ± 3888 −60**
TNF-α 187 ± 55 59 126 ± 18 211 −77**
a)Peritoneal elicitedmacrophages (PEMs) fromC57BL/6Jmicewere incu-
bated for 10 h with LPS (1 μg/mL) ± rmC5a (100 nM). CTRL denotes
supernatants from resting cells. Multiplexing bead-based assay. Data
are from four independent experiments. Values represent means ±
SEM and values after LPS alone were used as 100% to calculate %
change. Student’s two-tailed t-test, LPS versus LPS+C5a, *p < 0.05,
**p < 0.01, ***p < 0.001.
with LPS also displayed somewhat diminished ability to amplify
G-CSF compared to C5a (Fig. 1C). C5a enhanced G-CSF produc-
tion on the mRNA level was detected by real-time PCR (Fig. 1D).
No effects on G-CSF levels were seen when C5a was used alone in
the absence of the co-stimulus, LPS (Fig. 1C and D).
C5a is known to activate PI3K/Akt and MEK/ERK kinases in
innate immune cells [5, 14, 16, 21–23]. Using bead-based assays
with phosphorylation-specific antibodies, we confirmed that C5a
activated MEK1 and Akt (Fig. 1E and F). These signaling pathways
appeared to be relevant for mediating C5a-enhanced G-CSF pro-
duction. Blockade of PI3K/Akt with the small molecule inhibitor,
LY294002, and blockade of MEK1/2 with PD98059 or the highly
selective inhibitor, U0126, greatly reduced the release of G-CSF
from PEMs activated with LPS or the combination of LPS plus C5a
(Fig. 1G and H).
G-CSF production is resistant to the inhibitory effects
of C5a-induced IL-10
To further elucidate the mechanism by which C5a differentially
suppressed proinflammatory cytokines/chemokines, while upreg-
ulating G-CSF, we studied the role of IL-10. C5a selectively
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Figure 1. C5a-induced amplification of G-CSF production from macrophages. (A) PEMs from C57BL/6J mice were stimulated for 8 h with LPS
(1 μg/mL) alone or in combination with different doses of recombinant mouse C5a (10–100 nM) followed by detection of G-CSF by ELISA in
supernatant fluids. (B) Time course of G-CSF secretion from PEMs after LPS (1 μg/mL) alone or together with rmC5a (100 nM), ELISA. (C) Comparison
of activity of rmC5a (100 nM) and rmC5adesArg (100 nM) to enhance G-CSF in supernatants from LPS-activated PEMs, 8 h, ELISA. (D) Real-time PCR
of mRNA for G-CSF from PEMs left as untreated controls (Ctrl), after LPS (1 μg/mL), LPS plus C5a (100 nM), or C5a alone, 6 h. (E) Phospho-MEK1
(serine 217/serine 221) in PEMs after incubation with C5a (100 nM) and LPS (1 μg/mL) alone or in combination. Phosphorylation levels in untreated
cells were used as onefold, bead-based assay. (F) Phospho-Akt (threonine 308) after stimulation with C5a, LPS, or LPS plus C5a, bead-based assay.
(G) Relative release of G-CSF from LPS-activated PEMs after blockade of PI3K/Akt with LY294002 (25 μM) or MEK1/2 with PD98059 (50 μM) or U0126
(1 μM), 8 h, ELISA. All experiments were done with cells from C57BL/6J mice. (H) PEMs were treated with combinations of LPS, C5a, and LY294002
as indicated followed by quantitation of G-CSF, 8 h, ELISA. (I) PEMs (C57BL/6J) were incubated for 8 h with LPS alone or LPS plus rmIL-10 (10 ng/mL)
followed by detection in supernatants of IL-1β, IL-12(p40), G-CSF, IFN-γ, and TNF-α. Amounts of cytokines after LPS alone were used as 100% values,
bead-based assays. (J) Relative release of G-CSF in PEMs from C57BL/6J mice compared to PEMs from IL-10−/− mice after LPS ± C5a, 8 h, ELISA. All
data are shown as mean ± SEM of three to six samples pooled from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, Student’s
two-tailed t-test.
promoted the production of IL-10 from LPS-activated PEMs
(Table 1). We have recently reported that C5a-induced IL-10
release is essential for suppression of proinflammatory cytokines
such as IL-17A and IL-23 by C5a [15]. Interestingly, the release
of G-CSF was resistant to the inhibitory effects of recombinant
IL-10, even when used in high concentrations (Fig. 1I). At the
same time, proinflammatory cytokines (IL-1β, IL-12, IFN-γ, TNF-α)
were greatly reduced by IL-10 (Fig. 1I). When the production
of endogenous IL-10 was interrupted using PEMs from IL-10−/−
mice, no differences were seen in G-CSF production after LPS
alone or in combination with C5a (Fig. 1J). This is in clear con-
trast to mediators such as IL-12, IL-17A, or IL-23 for which the
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Figure 2. Studies on the production of G-CSF with genetic absence of the C5aR receptor or C5L2 receptor. (A) Relative release of G-CSF from PEMs
from C57BL/6J (Wt), C5aR−/−, or C5L2−/− mice after LPS (1 μg/mL) alone or together with C5a (100 nM), 8 h, ELISA. Results with LPS alone were used
as the 100% value for each mouse strain. (B) Detection of G-CSF in plasma of C57BL/6J mice 12 h after endotoxic shock (LPS 10 mg/kg body weight
i.p.). Mice were pretreated with neutralizing polyclonal anti-C5a antiserum or control (Ctrl) serum (500 μL i.p., n ≥ 7 per group), ELISA. (C) Plasma
concentrations of G-CSF in C57BL/6J (Wt) mice after sham-OP (n = 7) or cecal ligation and puncture (CLP, n = 15) compared with concentrations
after CLP in C5aR−/− mice (n = 14) or C5L2−/− mice (n = 11). Sham-OP was performed only with Wt mice, 24 h, ELISA. Data are shown as
mean + SEM of six wells pooled from three independent experiments (each done in duplicate, A), and mean + SEM of the indicated number of
mice pooled from one experiment (B) or two experiments (C). *p < 0.05, **p < 0.01, Student’s two-tailed t-test.
modulatory effects of C5a are mitigated with genetic deficiency or
antibody blockade of IL-10 [15,24,25].
Dependency of G-CSF release in the presence of C5aR
and C5L2
There is an ongoing debate on the precise functional roles of the
C5L2 receptor as compared to the C5aR receptor [1]. We used
PEMs from C5aR−/− mice and C5L2−/− mice to investigate the
roles of both receptors for C5a-mediated amplification of G-CSF.
Both C5aR and C5L2were required for C5a enhancement of G-CSF
production in cultures of PEMs from C5aR−/− mice and C5L2−/−
mice (Fig. 2A), since the absence of either receptor caused G-CSF
levels to fall to baseline levels (with LPS alone).
To study the effects of C5a on G-CSF production during the
acute inflammatory response in vivo, we blocked endogenous C5a
during endotoxic shock, which resulted in moderately decreased
G-CSF (Fig. 2B). Next, we used the model of polymicrobial sepsis
after CLP to study G-CSF production. Sham-operated C57BL/6J
mice received only anesthesia and laparotomy without manipula-
tion of the cecum. The amounts of G-CSF in plasma of sham-OP
mice were low but G-CSF was greatly increased in C57BL/6J mice
24 h after CLP (>1000 ng/mL, Fig. 2C). At the same time, plasma
concentrations of G-CSF were substantially lower in C5aR−/− mice
and C5L2−/− mice after CLP (Fig. 2C).
Collectively, it appears that neither C5a receptor (C5aR and
C5L2) by itself is able to compensate for the genetic absence of
the other receptor, respectively. These findings are quite surpris-
ing because C5a does not require presence of the C5L2 receptor
(as studied in C5L2−/− PEMs) for suppression of other cytokines
such as IL-17A, IL-23, or IL-27 [5,14], suggesting that the effects
of C5a on G-CSF production from PEMs are distinct from the
regulation of other mediators by C5a (Table 1). Interestingly,
a recent study has reported C5aR internalization after ligand
binding and co-localization with intracellular C5L2 in human
neutrophils, which may suggest a potential crosstalk of the two
receptors [26].
Complement activation is an essential arm of innate immune
responses, capable of providing immediate clearance of pathogens
by direct lysis (membrane attack complex) and facilitating
opsonization/phagocytosis of pathogens. C5a directs chemotaxis
of PMNs to the site of inflammation and activates such cells.
In addition, our data demonstrate that C5a signaling amplifies
the production of G-CSF in vitro and in vivo. G-CSF is a critical
growth factor for the proliferation of PMNs during hematopoiesis
in the bone marrow. Recombinant G-CSF is an FDA-approved
pharmaceutical drug for the treatment of chemotherapy-related
severe neutropenia. In one report, C5-deficient mice displayed
an impaired mobilization of hematopoietic stem/progenitor cells
[27]. C5a promotes the egress of PMNs from the bone marrow
into peripheral blood [28]. Our data suggest that C5a via enhanced
production of G-CSF may promote the PMN-dependent acute
inflammatory response with dependency on both C5aR and C5L2
receptors. Respiratory burst and granule release from PMNs
contributes to tissue injury during inflammation (e.g. in the
setting of sepsis). In accordance with our findings, the block-
ade of complement activation using compstatin analogs (which
block the C3 convertase) reduced G-CSF levels in human blood
during simulated hemodialysis [29]. Moreover, G-CSF appears
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to upregulate C5aR (CD88) expression on PMNs [28]. In sum-
mary, C5a promotes the influx and proliferation of PMNs through
multiple mechanisms, whereas different effects are seen with
respect to adaptive immunity such as suppression of Th1 and Th17
cytokines.
Concluding remarks
C5a possesses broad-spectrum activities for regulating the release
of inflammatory mediators from macrophages. G-CSF is regu-
lated by C5a different than with most other mediators. C5aR
and C5L2 are both indispensable for transmission of signal-




All procedures were in accordancewith the U.S. National Institutes
of Health guidelines and the University Committee on Use and
Care of Animals (UCUCA), University of Michigan. We used male
mice of the strains C57BL/6J, IL-10−/− (B6.129P2-Il10tm1Cgn;
Jackson Laboratories, Bar Harbor, ME, USA), C5aR−/−, and
C5L2−/− (both breeding and genotyping were done at the Univer-
sity of Michigan). Mice were housed under specific pathogen-free
conditions. The generation of C5aR−/− and C5L2−/− mice by tar-
geted gene disruption has been described previously [30,31]. Ani-
mals used were the progeny of at least ten generations of breeding
of the knockout mice on the C57BL/6J background.
Cecal ligation and puncture (CLP)
The CLP surgery was performed as described elsewhere [32].
Briefly, mice were anaesthetized with ketamine/xylazine i.p.
before laparotomy, ligation of 4–5 mm of the distal cecum
with puncture (21-G needle) and postoperative administration of
1 mL 0.9% NaCl subcutaneously. The severity of the procedure
was designed to obtain mortality rates of 20–50% after 7 days.
Sham mice received anesthetics, laparotomy, and fluid resuscita-
tion without manipulation of the cecum.
Peritoneal elicited macrophages (PEMs)
Thioglycollate (1.5 mL, 2.4%, i.p.) was injected to mice and
macrophages (>80% F4/80+CD11b+) obtained by peritoneal
lavage 4 days later [14]. PEMs were cultured at 2 × 106 cells/mL
in RPMI 1640 medium supplemented with 100 U/mL penicillin-
streptomycin, 0.1% BSA, and 25 mM HEPES at 37◦C and 5% CO2.
At the end of experiments, nonadherent cells were pelleted by cen-
trifugation (650 × g, 5 min, 4◦C) and supernatants were stored at
−80◦C until further analysis.
Detection of proteins
Mouse G-CSF was quantified by ELISA (R&D Systems) accord-
ing to the instructions of the manufacturer. Bead-based assays
were used for detection of phosphorylated MEK1 (serine 217/ser-
ine 221) (BioRad) or phosphorylated Akt (threonine 308) (Mil-
lipore). Cells were lysed in the presence of protease and phos-
phatase inhibitors (Bio-Plex Cell Lysis Kit, BioRad) and assays
performed according to instructions of the manufacturers. A mul-
tiplex bead-based assay (BioPlex Pro, 23-plex group I, BioRad)
was used for simultaneous quantification of the following
cytokines/chemokines: IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6,
IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-17, eotaxin (CCL11),
G-CSF, GM-CSF, IFN-γ, KC (CXCL1), MCP-1 (CCL2), MIP-1α
(CCL3), MIP-1β (CCL4), RANTES (CCL5), and TNF-α. All sam-
ples from bead-based assays were analyzed on a Luminex-200
instrument as described before [32].
Real-time PCR
Total RNA was isolated (RNeasy Mini Kit, Qiagen) and reverse
transcribed (TaqMen reagents) followed by real-time amplifica-
tion (SYBR Green Master Mix, Applied Biosystems) on a 7500
Real-Time PCR instrument (Applied Biosystems). The 2−CT
method with normalization to GAPDH and untreated controls
was used for calculation of results. Primers for mouse G-CSF
(#QT00105140) were purchased from Qiagen. Primer sequences
for mouse GAPDH were: (fo) 5′-TACCCCCAATGTGTCCGTCGTG-
3′, (re) 5′-CCTTCAGTGGGCCCTCAGATGC-3′.
Reagents
The following reagents were used for the studies: Recombi-
nant mouse C5a (R&D Systems and Hycult); LPS (Escherichia
coli, 0111:B4, Sigma-Aldrich); recombinant mouse C5adesArg
(Hycult); LY294002 (InvivoGen); PD98059 (InvivoGen); and
U0126 (InvivoGen). We used a neutralizing anti-C5a antiserum
as described before [14].
Statistical analysis
The GraphPad Prism Version 5.04 software was used for sta-
tistical analysis. All values are expressed as mean and error
bars represent SEM. Data sets were analyzed by two-tailed
Student’s t-test across independent experiments. In vitro exper-
iments were performed independently at least three times and in
vivo experiments were done with numbers of mice as indicated in
the figure legends. Differences were considered significant when
p < 0.05.
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